Records containing: Platinum-sensitive Ovarian Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-04-08
  A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
• CLINICAL_TRIALS study record update · 2026-03-06
  A Single-Arm, Exploratory, Multicenter Study Evaluating Iparomlimab/Tuvonralimab Combined With Standard Chemotherapy Followed by Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
• CLINICAL_TRIALS study record update · 2026-02-04
  Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
• CLINICAL_TRIALS study record update · 2025-04-16
  An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
• CLINICAL_TRIALS study record update · 2024-12-02
  Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2024-09-19
  A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors
• CLINICAL_TRIALS study record update · 2021-10-06
  Variance of HRD From Primary to Recurrent in High-grade Serous Ovarian Cancer